摘要
目的 研究植入式丝裂霉素 (MMC)控释剂对人肝癌裸鼠移植瘤的抑瘤作用。方法将 0 .0 4、0 .0 8、0 .16mg 3种不同剂量的丝裂霉素控释剂植入荷人肝癌裸小鼠皮下移植瘤内 ,并与MMC瘤内注射、MMC腹腔注射及对照组相比较 ,观察其抑瘤作用。结果 0 .16mg瘤内植入组抑瘤率明显高于对照组 (P =0 .0 0 1)及 0 .0 4mg瘤内植入组 ( P =0 .0 0 3)。 0 .16mg瘤内植入组抑瘤率也明显高于 0 .16mg腹腔注射组 (P =0 .0 0 3)。结论 植入式丝裂霉素控释剂是一种有效治疗原发性肝癌的药物新剂型 ,丝裂霉素控释剂瘤内植入可能成为临床治疗中晚期肝癌的新方法。
Objective To study the curative effect of implantable controlled release mitomycin C on hepatocellular carcinoma in nude mice.Methods Three different doses (0.04,0.08,0.16 mg) of implantable controlled release mitomycin C-loaded microcapsules were implant ed into highly metastatic models of human liver cancer (LCI-D20) and the curati ve effect was compared with those of conventional administration methods and pla cebo.Results Growth of the tumors were inhibited consider ably by implantable controlled release mitomycin C (P=0.001) in a dose-depe ndent manner (P=0.003).There was significant difference in tumor inhibiting rate between intratumorally implanted group and intraperitonal injection group ( P=0.003).Conclusion Implantable controlled release mi tomycin C is a novel reagent in the effective treatment of highly metastatic mod els of human liver cancer (LCI-D20) and may help pave the way for a new therape utic modality in treatment of advanced liver cancer.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2003年第4期367-368,共2页
Chinese Journal of Experimental Surgery
关键词
抑瘤作用
丝裂霉素
治疗
MMC
肝癌
Carcinoma,hepatocellular
Mitomycin C
Treatment
Implant
